Publications

2015

Mohamed A, Ayman A, Deniece J, Wang T, Kovach C, Siddiqui MT, et al. P62/Ubiquitin IHC Expression Correlated with Clinicopathologic Parameters and Outcome in Gastrointestinal Carcinomas. Front Oncol. 2015;5:70.
Rider JR, Fiorentino M, Kelly R, Gerke T, Jordahl K, Sinnott JA, et al. Tumor expression of adiponectin receptor 2 and lethal prostate cancer. Carcinogenesis. 2015;36(6):639-47.
Kiuru M, Camp B, Adhami K, Jacob V, Magro C, Wildman H. Treatment of metastatic cutaneous Crohn disease with certolizumab. Dermatol Online J. 2015;21(11).
Bellmunt J, Werner L, Bamias A, Fay AP, Park RS, Riester M, et al. HER2 as a target in invasive urothelial carcinoma. Cancer Med. 2015;4(6):844-52.
Weidner A-, Panarelli NC, Geyer JT, Bhavsar EB, Furman RR, Leonard JP, et al. Idelalisib-associated Colitis: Histologic Findings in 14 Patients. Am J Surg Pathol. 2015;39(12):1661-7.
Mitchell CJ, Getnet D, Kim M-, Manda SS, Kumar P, Huang T-, et al. A multi-omic analysis of human naïve CD4+ T cells. BMC Syst Biol. 2015;9:75.
Crescenzo R, Inghirami G. Anaplastic lymphoma kinase inhibitors. Curr Opin Pharmacol. 2015;23:39-44.
Zhan Y, Kost-Alimova M, Shi X, Leo E, Bardenhagen JP, Shepard HE, et al. Development of novel cellular histone-binding and chromatin-displacement assays for bromodomain drug discovery. Epigenetics Chromatin. 2015;8:37.
Johnson DP, Spitz GS, Tharkar S, Quayle SN, Shearstone JR, Jones S, et al. HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma. Oncotarget. 2015;6(7):4863-87.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700